Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.

NCT07333287 is registered in ClinicalTrials.gov with Shandong Provincial Hospital as lead sponsor.

NCT NCT07333287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07333287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.
Lead sponsor
Shandong Provincial Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 1, 2026
Completion date
November 30, 2028
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy-naive, pancreatic cancer liver metastases